Base Edited Natural Killer Cells NK510 clinical trials
Also written NK510.
How each study uses Base Edited Natural Killer Cells NK510 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Base Edited Natural Killer Cells NK510 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NK510
- 4
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Base Therapeutics (Shanghai) Co., Ltd. (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
Often tested with
Tested in the same studies.
Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · MT027 (1) · QH101 (1) · META10 (1) · TAEST1901 (1) · TCN 201 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Base Edited Natural Killer Cells NK510.
- Jun 2027Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal CancerEarly Phase 1 · Base Therapeutics (Shanghai) Co., Ltd.
Studies
Open first, then newest update. How each study uses Base Edited Natural Killer Cells NK510 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal CancerRecruitingEarly Phase 1Base Therapeutics (Shanghai) Co., Ltd.NCT07166263Written as NK510
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07307053Written as NK510
- Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue SarcomaRecruitingEarly Phase 1Base Therapeutics (Shanghai) Co., Ltd.NCT06117878Written as NK510
- Safety and Efficacy of NK510 to Treat Gastric CancerEnrolling by invitationEarly Phase 1Base Therapeutics (Shanghai) Co., Ltd.NCT06098898Written as NK510
- NK510 Cell Therapy for Refractory Systemic Lupus ErythematosusTerminatedEarly Phase 1Base Therapeutics (Shanghai) Co., Ltd.NCT07083349Written as NK510 : allogeneic genetic modified NK